FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like Import Alert Issued to Chinese API Manufacturer June 29, 2023 Kmart to Settle FCA Violation Allegations for $32.2 Million December 28, 2017 Pfizer-BioNTech COVID-19 Vaccine Moves Into Pivotal Trial August 20, 2020